Search

Your search keyword '"Lutgens, Ludy"' showing total 300 results
Start Over Author "Lutgens, Ludy"
300 results on '"Lutgens, Ludy"'

51. Automated causal inference in application to randomized controlled clinical trials

Author

MS Radiotherapie, Cancer, Wu, Ji Q., Horeweg, Nanda, de Bruyn, Marco, Nout, Remi A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Jobsen, Jan J., van der Steen-Banasik, Elzbieta M., Nijman, Hans W., Smit, Vincent T.H.B.M., Bosse, Tjalling, Creutzberg, Carien L., Koelzer, Viktor H., MS Radiotherapie, Cancer, Wu, Ji Q., Horeweg, Nanda, de Bruyn, Marco, Nout, Remi A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Jobsen, Jan J., van der Steen-Banasik, Elzbieta M., Nijman, Hans W., Smit, Vincent T.H.B.M., Bosse, Tjalling, Creutzberg, Carien L., and Koelzer, Viktor H.

Published
2022

52. Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future

Author

MS Radiotherapie, Cancer, Spampinato, Sofia, Jensen, Nina B.K., Pötter, Richard, Fokdal, Lars U., Chargari, Cyrus, Lindegaard, Jacob C., Schmid, Maximilian P., Sturdza, Alina, Jürgenliemk-Schulz, Ina M., Mahantshetty, Umesh, Hoskin, Peter, Segedin, Barbara, Rai, Bhavana, Bruheim, Kjersti, Wiebe, Ericka, Van der Steen-Banasik, Elzbieta, Cooper, Rachel, Van Limbergen, Erik, Sundset, Marit, Pieters, Bradley R., Lutgens, Ludy C.H.W., Tan, Li Tee, Villafranca, Elena, Smet, Stéphanie, Jastaniyah, Noha, Nout, Remi A., Kirisits, Christian, Chopra, Supriya, Kirchheiner, Kathrin, Tanderup, Kari, EMBRACE Collaborative Group, Collaborative Group, MS Radiotherapie, Cancer, Spampinato, Sofia, Jensen, Nina B.K., Pötter, Richard, Fokdal, Lars U., Chargari, Cyrus, Lindegaard, Jacob C., Schmid, Maximilian P., Sturdza, Alina, Jürgenliemk-Schulz, Ina M., Mahantshetty, Umesh, Hoskin, Peter, Segedin, Barbara, Rai, Bhavana, Bruheim, Kjersti, Wiebe, Ericka, Van der Steen-Banasik, Elzbieta, Cooper, Rachel, Van Limbergen, Erik, Sundset, Marit, Pieters, Bradley R., Lutgens, Ludy C.H.W., Tan, Li Tee, Villafranca, Elena, Smet, Stéphanie, Jastaniyah, Noha, Nout, Remi A., Kirisits, Christian, Chopra, Supriya, Kirchheiner, Kathrin, Tanderup, Kari, and EMBRACE Collaborative Group, Collaborative Group

Published
2022

54. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data

Author

Nout, Remi A., Putter, Hein, Jürgenliemk-Schulz, Ina M., Jobsen, Jan J., Lutgens, Ludy C.H.W., van der Steen-Banasik, Elzbieta M., Mens, Jan Willem M., Slot, Annerie, Stenfert Kroese, Marika C., Nijman, Hans W., van de Poll-Franse, Lonneke V., and Creutzberg, Carien L.

Published
2012
Full Text
View/download PDF

55. Risk Factors for Late Persistent Fatigue After Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: An Analysis From the EMBRACE-I Study

Author

Smet, Stéphanie, primary, Spampinato, Sofia, additional, Pötter, Richard, additional, Jürgenliemk-Schulz, Ina M., additional, Nout, Remi A., additional, Chargari, Cyrus, additional, Mahantshetty, Umesh, additional, Sturdza, Alina, additional, Segedin, Barbara, additional, Bruheim, Kjersti, additional, Hoskin, Peter, additional, Rai, Bhavana, additional, Huang, Fleur, additional, Cooper, Rachel, additional, Van der Steen-Banasik, Elzbieta, additional, Sundset, Marit, additional, Van Limbergen, Erik, additional, Tan, Li Tee, additional, Lutgens, Ludy C.H.W., additional, Villafranca, Elena, additional, Pieters, Bradley R., additional, Tanderup, Kari, additional, and Kirchheiner, Kathrin, additional

Published
2022
Full Text
View/download PDF

56. Meeting Report: Synopsis of Partial-Body Radiation Diagnostic Biomarkers and Medical Management of Radiation Injury Workshop

Author

Prasanna, Pataje G. S., Blakely, William F., Bertho, Jean-Marc, Chute, John P., Cohen, Eric P., Goans, Ronald E., Grace, Marcy B., Lillis-Hearne, Patricia K., Lloyd, David C., Lutgens, Ludy C. H. W., Meineke, Viktor, Ossetrova, Natalia I., Romanyukha, Alexander, Saba, Julie D., Weisdorf, Daniel J., Wojcik, Andrzej, Yukihara, Eduardo G., and Pellmar, Terry C.

Published
2010
Full Text
View/download PDF

57. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy

Author

Wortman, Bastiaan G., primary, Post, Cathalijne C.B., additional, Powell, Melanie E., additional, Khaw, Pearly, additional, Fyles, Anthony, additional, D'Amico, Romerai, additional, Haie-Meder, Christine, additional, Jürgenliemk-Schulz, Ina M., additional, McCormack, Mary, additional, Do, Viet, additional, Katsaros, Dionyssios, additional, Bessette, Paul, additional, Baron, Marie Hélène, additional, Nout, Remi A., additional, Whitmarsh, Karen, additional, Mileshkin, Linda, additional, Lutgens, Ludy C.H.W., additional, Kitchener, Henry C., additional, Brooks, Susan, additional, Nijman, Hans W., additional, Astreinidou, Eleftheria, additional, Putter, Hein, additional, Creutzberg, Carien L., additional, and de Boer, Stephanie M., additional

Published
2022
Full Text
View/download PDF

58. Interpretable Deep Learning Predicts the Molecular Endometrial Cancer Classification from H&E Images: A Combined Analysis of the Portec Randomized Clinical Trials

Author

Fremond, Sarah, primary, Andani, Sonali, additional, Barkey Wolf, Jurriaan, additional, Dijkstra, Jouke, additional, Melsbach, Sinead, additional, Jobsen, Jan J., additional, Brinkhuis, Mariel, additional, Roothaan, Suzan, additional, Jurgenliemk-Schulz, Ina, additional, Lutgens, Ludy CHW, additional, Nout, Remi A., additional, van der Steen-Banasik, Elzbieta M., additional, de Boer, Stephanie M., additional, Powell, Melanie E., additional, Singh, Naveena, additional, Mileshkin, Linda R., additional, Mackay, Helen J., additional, Leary, Alexandra, additional, Nijman, Hans W., additional, Smit, Vincent THBM, additional, Creutzberg, Carien L., additional, Horeweg, Nanda, additional, Koelzer, Viktor H., additional, and Bosse, Tjalling, additional

Published
2022
Full Text
View/download PDF

59. Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer

Author

Peters, Elke E.M., primary, León-Castillo, Alicia, additional, Smit, Vincent T.H.B.M., additional, Boennelycke, Marie, additional, Hogdall, Estrid, additional, Hogdall, Claus, additional, Creutzberg, Carien, additional, Jürgenliemk-Schulz, Ina M., additional, Jobsen, Jan J., additional, Mens, Jan Willem M., additional, Lutgens, Ludy C.H.W., additional, van der Steen-Banasik, Elzbieta M., additional, Ortoft, Gitte, additional, Bosse, Tjalling, additional, and Nout, Remi, additional

Published
2021
Full Text
View/download PDF

60. Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial

Author

Post, C, de Boer, S, Powell, M, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, Ottevanger, N, Ledermann, J, Khaw, P, D'Amico, R, Fyles, A, Baron, M, Kitchener, H, Nijman, H, Lutgens, L, Brooks, S, Jürgenliemk-Schulz, I, Feeney, A, Goss, G, Fossati, R, Ghatage, P, Leary, A, Do, V, Lissoni, A, Mccormack, M, Nout, R, Verhoeven-Adema, K, Smit, V, Putter, H, Creutzberg, C, Post, Cathalijne C B, de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Nelleke P B, Ledermann, Jonathan A, Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie Hélène, Kitchener, Henry C, Nijman, Hans W, Lutgens, Ludy C H W, Brooks, Susan, Jürgenliemk-Schulz, Ina M, Feeney, Amanda, Goss, Geraldine, Fossati, Roldano, Ghatage, Prafull, Leary, Alexandra, Do, Viet, Lissoni, Andrea A, McCormack, Mary, Nout, Remi A, Verhoeven-Adema, Karen W, Smit, Vincent T H B M, Putter, Hein, Creutzberg, Carien L, Post, C, de Boer, S, Powell, M, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, Ottevanger, N, Ledermann, J, Khaw, P, D'Amico, R, Fyles, A, Baron, M, Kitchener, H, Nijman, H, Lutgens, L, Brooks, S, Jürgenliemk-Schulz, I, Feeney, A, Goss, G, Fossati, R, Ghatage, P, Leary, A, Do, V, Lissoni, A, Mccormack, M, Nout, R, Verhoeven-Adema, K, Smit, V, Putter, H, Creutzberg, C, Post, Cathalijne C B, de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Nelleke P B, Ledermann, Jonathan A, Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie Hélène, Kitchener, Henry C, Nijman, Hans W, Lutgens, Ludy C H W, Brooks, Susan, Jürgenliemk-Schulz, Ina M, Feeney, Amanda, Goss, Geraldine, Fossati, Roldano, Ghatage, Prafull, Leary, Alexandra, Do, Viet, Lissoni, Andrea A, McCormack, Mary, Nout, Remi A, Verhoeven-Adema, Karen W, Smit, Vincent T H B M, Putter, Hein, and Creutzberg, Carien L

Abstract

Background: The survival results of the PORTEC-3 trial showed a significant improvement in both overall and failure-free survival with chemoradiotherapy versus pelvic radiotherapy alone. The present analysis was performed to compare long-term adverse events (AE) and health-related quality of life (HRQOL). Patients and methods: 660 women with high-risk endometrial cancer were randomly assigned to receive chemoradiotherapy (2 concurrent cycles of cisplatin followed by 4 cycles of carboplatin/paclitaxel) or radiotherapy alone. Toxicity was graded using CTCAE v3.0. HRQOL was measured using EORTC QLQ-C30 and CX24/OV28-subscales and compared to normative-data. An as-treated analysis was performed. Results: Median follow up was 74.6 months; 574 (87%) patients were evaluable for HRQOL. At 5 years, grade ≥2 AE were scored for 78 (38%) patients who had received chemoradiotherapy versus 46 (24%) who had received radiotherapy (p=0.008). Grade 3 AE did not differ significantly between the groups (8% vs 5%, p=0.18) at 5 years, and only one new late grade 4 toxicity had been reported. At 3 and 5 years, sensory neuropathy toxicity grade ≥2 persisted after chemoradiotherapy in 6% (vs 0% after radiotherapy, p<0.001) and more patients reported significant tingling or numbness at HRQOL (27% vs 8%, p<0.001 at 3 years; 24% vs 9%, p=0.002 at 5 years). Until 3 years, more patients who had chemoradiotherapy reported limb weakness (21% vs 5%, p<0.001) and lower physical (79 vs 87, p<0.001) and role functioning (78 vs 88, p<0.001) scores. Both treatment groups reported similar long-term global health/QOL scores, which were better than those of the normative-population. Conclusion: This study shows a long-lasting, clinically relevant, negative impact of chemoradiotherapy on toxicity and HRQOL, most importantly persistent peripheral sensory neuropathy. Physical and role functioning impairments were seen until 3 years. These long-term data are essential for patient information and

Published
2021

61. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer:Implications for shared decision making

Author

Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., Creutzberg, Carien L., Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., and Creutzberg, Carien L.

Abstract

Background: Decision making regarding adjuvant therapy for high-risk endometrial cancer is complex. The aim of this study was to determine patients' and clinicians' minimally desired survival benefit to choose chemoradiotherapy over radiotherapy alone. Moreover, influencing factors and importance of positive and negative treatment effects (i.e. attribute) were investigated. Methods: Patients with high-risk endometrial cancer treated with adjuvant pelvic radiotherapy with or without chemotherapy and multidisciplinary gynaecologic oncology clinicians completed a trade-off questionnaire based on PORTEC-3 trial data. Results: In total, 171 patients and 63 clinicians completed the questionnaire. Median minimally desired benefit to make chemoradiotherapy worthwhile was significantly higher for patients versus clinicians (10% vs 5%, p = 0.02). Both patients and clinicians rated survival benefit most important during decision making, followed by long-term symptoms. Older patients (OR 0.92 [95%CI 0.87–0.97]; p = 0.003) with comorbidity (OR 0.34 [95% CI 0.12–0.89]; p = 0.035) had lower preference for chemoradiotherapy, while patients with better numeracy skills (OR 1.2 [95%CI 1.05–1.36], p = 0.011) and chemoradiotherapy history (OR 25.0 [95%CI 8.8–91.7]; p < 0.001) had higher preference for chemoradiotherapy. Conclusions: There is a considerable difference in minimally desired survival benefit of chemoradiotherapy in high-risk endometrial cancer among and between patients and clinicians. Overall, endometrial cancer patients needed higher benefits than clinicians before preferring chemoradiotherapy.

Published
2021

62. Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva:An efficacy study

Author

van Triest, Baukelien, Rasing, Marnix, van der Velden, Jacobus, de Hullu, Joanne, Witteveen, Petronella O., Beukema, Jannet C., van der Steen-Banasik, Elsbieta, Westerveld, Henrike, Snyers, An, Peters, Max, Creutzberg, Carien L., Nout, Remi A., Lutgens, Ludy, Jürgenliemk-Schulz, Ina, van Triest, Baukelien, Rasing, Marnix, van der Velden, Jacobus, de Hullu, Joanne, Witteveen, Petronella O., Beukema, Jannet C., van der Steen-Banasik, Elsbieta, Westerveld, Henrike, Snyers, An, Peters, Max, Creutzberg, Carien L., Nout, Remi A., Lutgens, Ludy, and Jürgenliemk-Schulz, Ina

Abstract

Objective: To evaluate feasibility of chemoradiation as alternative for extensive surgery in patients with locally advanced vulvar cancer and to report on locoregional control, toxicity and survival. Methods: In a multicenter, prospective phase II trial patients with locally advanced vulvar cancer were treated with locoregional radiotherapy combined with sensitizing chemotherapy (capecitabine). Treatment feasibility, percentage locoregional control, survival and toxicity were evaluated. Results: 52 patients with mainly T2/T3 disease were treated according to the study protocol in 10 centers in the Netherlands from 2007 to 2019. Full dose radiotherapy (tumor dose of 64.8Gy) was delivered in 92% and full dose capecitabine in 69% of patients. Most prevalent acute ≥ grade 3 toxicities were regarding skin/mucosa and pain (54% and 37%). Late ≥grade 3 toxicity was reported for skin/mucosa (10%), fibrosis (4%), GI incontinence (4%) and stress fracture or osteoradionecrosis (4%). Twelve weeks after treatment, local clinical complete response (cCR) and regional control (RC) rates were 62% and 75%, respectively. After 2 years, local cCR persisted in 22 patients (42%) and RC was 58%. Thirty patients (58%) had no evidence of disease at end of follow-up (median 35 months). In 9 patients (17%) extensive surgery with stoma formation was needed. Progression free survival was 58%, 51% and 45% and overall survival was 76%, 66%, 52% at 1,2, and 5 years. Conclusions: Definitive capecitabine-based chemoradiation as alternative for extensive surgery is feasible in locally advanced vulvar cancer and results in considerable locoregional control with acceptable survival rates with manageable acute and late toxicity.

Published
2021

63. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making

Author

MS Radiotherapie, Cancer, Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., Creutzberg, Carien L., MS Radiotherapie, Cancer, Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., and Creutzberg, Carien L.

Published
2021

64. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

Author

MS Radiotherapie, Cancer, Post, Cathalijne C.B., de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Nelleke (P ).B., Ledermann, Jonathan A., Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie Hélène, Kitchener, Henry C., Nijman, Hans W., Lutgens, Ludy C.H.W., Brooks, Susan, Jürgenliemk-Schulz, Ina M., Feeney, Amanda, Goss, Geraldine, Fossati, Roldano, Ghatage, Prafull, Leary, Alexandra, Do, Viet, Lissoni, Andrea A., McCormack, Mary, Nout, Remi A., Verhoeven-Adema, Karen W., Smit, Vincent T.H.B.M., Putter, Hein, Creutzberg, Carien L., MS Radiotherapie, Cancer, Post, Cathalijne C.B., de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Nelleke (P ).B., Ledermann, Jonathan A., Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie Hélène, Kitchener, Henry C., Nijman, Hans W., Lutgens, Ludy C.H.W., Brooks, Susan, Jürgenliemk-Schulz, Ina M., Feeney, Amanda, Goss, Geraldine, Fossati, Roldano, Ghatage, Prafull, Leary, Alexandra, Do, Viet, Lissoni, Andrea A., McCormack, Mary, Nout, Remi A., Verhoeven-Adema, Karen W., Smit, Vincent T.H.B.M., Putter, Hein, and Creutzberg, Carien L.

Published
2021

65. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer

Author

MS Radiotherapie, Cancer, Post, Cathalijne C.B., Stelloo, Ellen, Smit, Vincent T.H.B.M., Ruano, Dina, Tops, Carli M., Vermij, Lisa, Rutten, Tessa A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Jobsen, Jan J., Nout, Remi A., Crosbie, Emma J., Powell, Melanie E., Mileshkin, Linda, Leary, Alexandra, Bessette, Paul, Putter, Hein, de Boer, Stephanie M., Horeweg, Nanda, Nielsen, Maartje, Wezel, Tom van, Bosse, Tjalling, Creutzberg, Carien L., MS Radiotherapie, Cancer, Post, Cathalijne C.B., Stelloo, Ellen, Smit, Vincent T.H.B.M., Ruano, Dina, Tops, Carli M., Vermij, Lisa, Rutten, Tessa A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Jobsen, Jan J., Nout, Remi A., Crosbie, Emma J., Powell, Melanie E., Mileshkin, Linda, Leary, Alexandra, Bessette, Paul, Putter, Hein, de Boer, Stephanie M., Horeweg, Nanda, Nielsen, Maartje, Wezel, Tom van, Bosse, Tjalling, and Creutzberg, Carien L.

Published
2021

66. Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study

Author

Onderzoek Radiotherapie, Cancer, MS Radiotherapie, MS Medische Oncologie, Arts-assistenten Radiotherapie, van Triest, Baukelien, Rasing, Marnix, van der Velden, Jacobus, de Hullu, Joanne, Witteveen, Petronella O., Beukema, Jannet C., van der Steen-Banasik, Elsbieta, Westerveld, Henrike, Snyers, An, Peters, Max, Creutzberg, Carien L., Nout, Remi A., Lutgens, Ludy, Jürgenliemk-Schulz, Ina, Onderzoek Radiotherapie, Cancer, MS Radiotherapie, MS Medische Oncologie, Arts-assistenten Radiotherapie, van Triest, Baukelien, Rasing, Marnix, van der Velden, Jacobus, de Hullu, Joanne, Witteveen, Petronella O., Beukema, Jannet C., van der Steen-Banasik, Elsbieta, Westerveld, Henrike, Snyers, An, Peters, Max, Creutzberg, Carien L., Nout, Remi A., Lutgens, Ludy, and Jürgenliemk-Schulz, Ina

Published
2021

69. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study

Author

Pötter, Richard, primary, Tanderup, Kari, additional, Schmid, Maximilian Paul, additional, Jürgenliemk-Schulz, Ina, additional, Haie-Meder, Christine, additional, Fokdal, Lars Ulrik, additional, Sturdza, Alina Emiliana, additional, Hoskin, Peter, additional, Mahantshetty, Umesh, additional, Segedin, Barbara, additional, Bruheim, Kjersti, additional, Huang, Fleur, additional, Rai, Bhavana, additional, Cooper, Rachel, additional, van der Steen-Banasik, Elzbieta, additional, Van Limbergen, Erik, additional, Pieters, Bradley Rumwell, additional, Tan, Li-Tee, additional, Nout, Remi Abubakar, additional, De Leeuw, Astrid Agatha Catharina, additional, Ristl, Robin, additional, Petric, Primoz, additional, Nesvacil, Nicole, additional, Kirchheiner, Kathrin, additional, Kirisits, Christian, additional, Lindegaard, Jacob Christian, additional, Chargari, Cyrus, additional, Dumas, Isabelle, additional, Lowe, Gerry, additional, Swamidas, Jamema, additional, Hudej, Robert, additional, Paulsen Hellebust, Taran, additional, Menon, Geetha, additional, Oinam, Arun S., additional, Bownes, Peter, additional, Christiaens, Melissa, additional, De Brabandere, Marisol, additional, Janssen, Hilde, additional, Oosterveld, Bernard, additional, Koedooder, Kees, additional, Langeland Marthinsen, Anne Beate, additional, Sundset, Marit, additional, Whitney, Diane, additional, Ketelaars, Martijn, additional, Lutgens, Ludy C.H.W., additional, Reinniers, Brigitte, additional, Mora, Itxa, additional, Villafranca, Elena, additional, Antal, Gergely, additional, Hadjiev, Janaki, additional, Bachand, Francois, additional, Batchelar, Deidre, additional, Erickson, Beth, additional, Rownd, Jason, additional, Jacobson, Geraldine, additional, Kim, Yusung, additional, Anttila, Maarit, additional, Palmgren, Jan-Erik, additional, An, Jusheng, additional, Assenholt, Marianne Sanggaard, additional, Banerjee, Susovan, additional, Bentzen, Sören, additional, Berger, Thomas, additional, Dankulchai, Pittaya, additional, Diendorfer, Tamara, additional, Dilworth, Ian, additional, Dimopoulos, Johannes, additional, Dörr, Elke, additional, Ecker, Stefan, additional, Federico, Mario, additional, Fidarova, Elena, additional, Fortin, Israel, additional, Georg, Petra, additional, Gora, Joanna, additional, Hegazy, Neamat, additional, Jastaniyah, Noha, additional, Jensen, Nina Boje Kibsgaard, additional, Liederer, Thomas, additional, Majercakova, Katarina, additional, Misimovic, Dragan, additional, Motisi, Laura, additional, Najjari Jamal, Dina, additional, Nkiwane, Karen, additional, Schwartz-Vittrup, Anders, additional, Serban, Monica, additional, Smet, Stephanie, additional, Spampinato, Sofia, additional, Trnkova, Petra, additional, Valgma, Margit, additional, Westerveld, Henrike, additional, Wong, Joyce Siu Yu, additional, and Yoshida, Kenji, additional

Published
2021
Full Text
View/download PDF

70. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer

Author

Post, Cathalijne C B, primary, Stelloo, Ellen, additional, Smit, Vincent T H B M, additional, Ruano, Dina, additional, Tops, Carli M, additional, Vermij, Lisa, additional, Rutten, Tessa A, additional, Jürgenliemk-Schulz, Ina M, additional, Lutgens, Ludy C H W, additional, Jobsen, Jan J, additional, Nout, Remi A, additional, Crosbie, Emma J, additional, Powell, Melanie E, additional, Mileshkin, Linda, additional, Leary, Alexandra, additional, Bessette, Paul, additional, Putter, Hein, additional, de Boer, Stephanie M, additional, Horeweg, Nanda, additional, Nielsen, Maartje, additional, Wezel, Tom van, additional, Bosse, Tjalling, additional, and Creutzberg, Carien L, additional

Published
2021
Full Text
View/download PDF

71. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

Author

Post, Cathalijne C.B., primary, de Boer, Stephanie M., additional, Powell, Melanie E., additional, Mileshkin, Linda, additional, Katsaros, Dionyssios, additional, Bessette, Paul, additional, Haie-Meder, Christine, additional, Ottevanger, Nelleke (P.) B., additional, Ledermann, Jonathan A., additional, Khaw, Pearly, additional, D'Amico, Romerai, additional, Fyles, Anthony, additional, Baron, Marie Hélène, additional, Kitchener, Henry C., additional, Nijman, Hans W., additional, Lutgens, Ludy C.H.W., additional, Brooks, Susan, additional, Jürgenliemk-Schulz, Ina M., additional, Feeney, Amanda, additional, Goss, Geraldine, additional, Fossati, Roldano, additional, Ghatage, Prafull, additional, Leary, Alexandra, additional, Do, Viet, additional, Lissoni, Andrea A., additional, McCormack, Mary, additional, Nout, Remi A., additional, Verhoeven-Adema, Karen W., additional, Smit, Vincent T.H.B.M., additional, Putter, Hein, additional, and Creutzberg, Carien L., additional

Published
2021
Full Text
View/download PDF

73. Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study

Author

Vittrup, Anders S., primary, Tanderup, Kari, additional, Bentzen, Søren M., additional, Jensen, Nina B.K., additional, Spampinato, Sofia, additional, Fokdal, Lars U., additional, Lindegaard, Jacob C., additional, Sturdza, Alina, additional, Schmid, Maximilian, additional, Segedin, Barbara, additional, Jürgenliemk-Schulz, Ina M., additional, Bruheim, Kjersti, additional, Mahantshetty, Umesh, additional, Haie-Meder, Christine, additional, Rai, Bhavana, additional, Cooper, Rachel, additional, van der Steen-Banasik, Elzbieta, additional, Sundset, Marit, additional, Huang, Fleur, additional, Nout, Remi A., additional, Villafranca, Elena, additional, Van Limbergen, Erik, additional, Pieters, Bradley R., additional, Tan, Li Tee, additional, Lutgens, Ludy C.H.W., additional, Hoskin, Peter, additional, Pötter, Richard, additional, and Kirchheiner, Kathrin, additional

Published
2021
Full Text
View/download PDF

74. Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer

Author

Horeweg, Nanda, primary, de Bruyn, Marco, additional, Nout, Remi A., additional, Stelloo, Ellen, additional, Kedzierska, Katarzyna, additional, León-Castillo, Alicia, additional, Plat, Annechien, additional, Mertz, Kirsten D., additional, Osse, Michelle, additional, Jürgenliemk-Schulz, Ina M., additional, Lutgens, Ludy C.H.W., additional, Jobsen, Jan J., additional, van der Steen-Banasik, Elzbieta M., additional, Smit, Vincent T., additional, Creutzberg, Carien L., additional, Bosse, Tjalling, additional, Nijman, Hans W., additional, Koelzer, Viktor H., additional, and Church, David N., additional

Published
2020
Full Text
View/download PDF

75. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

Author

van den Heerik, Anne Sophie V M, primary, Horeweg, Nanda, additional, Nout, Remi A, additional, Lutgens, Ludy C H W, additional, van der Steen-Banasik, Elzbieta M, additional, Westerveld, G Henrike, additional, van den Berg, Hetty A, additional, Slot, Annerie, additional, Koppe, Friederike L A, additional, Kommoss, Stefan, additional, Mens, Jan Willem M, additional, Nowee, Marlies E, additional, Bijmolt, Stefan, additional, Cibula, David, additional, Stam, Tanja C, additional, Jurgenliemk-Schulz, Ina M, additional, Snyers, An, additional, Hamann, Moritz, additional, Zwanenburg, Aleida G, additional, Coen, Veronique L M A, additional, Vandecasteele, Katrien, additional, Gillham, Charles, additional, Chargari, Cyrus, additional, Verhoeven-Adema, Karen W, additional, Putter, Hein, additional, van den Hout, Wilbert B, additional, Wortman, Bastiaan G, additional, Nijman, Hans W, additional, Bosse, Tjalling, additional, and Creutzberg, Carien L, additional

Published
2020
Full Text
View/download PDF

76. Nine Recommendations for Decision Aid Implementation from the Clinician Perspective

Author

Ankolekar, Anshu, primary, Vanneste, Ben G.L., additional, Gurp, Esther Bloemen-van, additional, Roermund, Joep van, additional, Berlanga, Adriana, additional, Roumen, Cheryl, additional, Limbergen, Evert van, additional, Lutgens, Ludy, additional, Marcelissen, Tom, additional, Lambin, Philippe, additional, Dekker, Andre, additional, and Fijten, Rianne, additional

Published
2020
Full Text
View/download PDF

77. Development of a Management Algorithm for Acute and Chronic Radiation Urethritis and Cystitis.

Author

Vanneste, Ben G.L., Van Limbergen, Evert J., Marcelissen, Tom A., van Roermund, Joep G.H., Lutgens, Ludy C., Arnoldussen, Carsten W.K.P., Lambin, Philippe, and Oelke, Matthias

Subjects
INTRAVESICAL administration, URETHRITIS, HYPERBARIC oxygenation, CYSTITIS, SURGICAL robots, INTERSTITIAL cystitis, THERAPEUTICS
Abstract

Objective: The purpose of this review was to summarize the current literature on the assessment and treatment of radiation urethritis and cystitis (RUC) for the development of an evidenced-based management algorithm. Material and Methods: The PubMed/MEDLINE database was searched by a multidisciplinary group of experts in January 2021. Results: In total, 48 publications were identified. Three different types of RUC can be observed in clinical practice: inflammation-predominant, bleeding-predominant, and the combination of inflammation- and bleeding-RUC. There is no consensus on the optimal treatment of RUC. Inflammation-predominant RUC should be treated symptomatically based on the existence of bothersome storage or voiding lower urinary tract symptom as well as on pain. When bleeding-predominant RUC has occurred, hydration and hyperbaric oxygen therapy (HOT) should be used first and, if HOT is not available, oral drugs instead (sodium pentosane polysulfate, aminocaproic acid, immunokine WF 10, conjugated estrogene, or pentoxifylline + vitamin E). If local bleeding persists, focal therapy of bleeding vessels with a laser or electrocoagulation is indicated. In case of generalized bleeding, intravesical installation should be initiated (formalin, aluminium salts, and hyaluronic acid/chondroitin). Vessel embolization is a less invasive treatment with potentially less complications and good clinical outcomes. Open- or robot-assisted surgery is indicated in patients with permanent, life-threatening bleeding, or fistulae. Conclusions: Treatment of RUC, if not self-limiting, should be done according to the type of RUC and in a stepwise approach. Conservative/medical treatment (oral and topic agents) should primarily be used before invasive (transurethral) treatments. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

83. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3) : final results of an international, open-label, multicentre, randomised, phase 3 trial

Author

de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B., Ledermann, Jonathan A., Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie Helene, Jürgenliemk-Schulz, Ina M., Kitchener, Henry C., Nijman, Hans W., Wilson, Godfrey, Brooks, Susan, Carinelli, Silvestro, Provencher, Diane, Hanzen, Chantal, Lutgens, Ludy C.H.W., Smit, Vincent T.H.B.M., Singh, Naveena, Do, Viet, D'Amico, Romerai, Nout, Remi A., Feeney, Amanda, Verhoeven-Adema, Karen W., Putter, Hein, Creutzberg, Carien L., McCormack, Mary, Whitmarsh, Karen, Allerton, Rozenn, Gregory, Deborah, Symonds, Paul, Hoskin, Peter J., Adusumalli, Madhavi, Anand, Anjana, Wade, Robert, Stewart, Alexandra, Taylor, Wendy, Kruitwagen, Roy F.P.M., Hollema, Harry, Pras, Elizabeth, Snyers, An, Stalpers, Lukas, Jobsen, Jan J., Slot, Annerie, Mens, Jan Willem M., and Stam, Tanja C.

Subjects
Canada, Time Factors, Endometrial Neoplasms/mortality, Clinical Trial, Phase III, Risk Factors, Paclitaxel/administration & dosage, Journal Article, Humans, Comparative Study, Aged, Neoplasm Staging, Gynecologic Surgical Procedures/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Research Support, Non-U.S. Gov't, Australia, Carboplatin/administration & dosage, Chemoradiotherapy, Adjuvant/adverse effects, Middle Aged, Europe, Multicenter Study, Treatment Outcome, Oncology, Randomized Controlled Trial, Carcinoma, Endometrioid/mortality, Lymph Node Excision, Female, Radiotherapy, Adjuvant, Dose Fractionation, Radiation, Neoplasm Grading, Cisplatin/administration & dosage, New Zealand
Abstract

BACKGROUND: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer. METHODS: PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical trials collaborating in the Gynaecological Cancer Intergroup. Eligible women had high-risk endometrial cancer with FIGO 2009 stage I, endometrioid-type grade 3 with deep myometrial invasion or lymph-vascular space invasion (or both), endometrioid-type stage II or III, or stage I to III with serous or clear cell histology. Women were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days per week) or radiotherapy and chemotherapy (consisting of two cycles of cisplatin 50 mg/m 2 given during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m 2) using a biased-coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage of cancer, and histological type. The co-primary endpoints were overall survival and failure-free survival. We used the Kaplan-Meier method, log-rank test, and Cox regression analysis for final analysis by intention to treat and adjusted for stratification factors. The study was closed on Dec 20, 2013, after achieving complete accrual; follow-up is ongoing. PORTEC-3 is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138. RESULTS: 686 women were enrolled between Nov 23, 2006, and Dec 20, 2013. 660 eligible patients were included in the final analysis, of whom 330 were assigned to chemoradiotherapy and 330 were assigned to radiotherapy. Median follow-up was 60·2 months (IQR 48·1-73·1). 5-year overall survival was 81·8% (95% CI 77·5-86·2) with chemoradiotherapy versus 76·7% (72·1-81·6) with radiotherapy (adjusted hazard ratio [HR] 0·76, 95% CI 0·54-1·06; p=0·11); 5-year failure-free survival was 75·5% (95% CI 70·3-79·9) versus 68·6% (63·1-73·4; HR 0·71, 95% CI 0·53-0·95; p=0·022). Grade 3 or worse adverse events during treatment occurred in 198 (60%) of 330 who received chemoradiotherapy versus 41 (12%) of 330 patients who received radiotherapy (p

Published
2018

84. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Author

MS Radiotherapie, Cancer, de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B., Ledermann, Jonathan A., Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie Helene, Jürgenliemk-Schulz, Ina M., Kitchener, Henry C., Nijman, Hans W., Wilson, Godfrey, Brooks, Susan, Carinelli, Silvestro, Provencher, Diane, Hanzen, Chantal, Lutgens, Ludy C.H.W., Smit, Vincent T.H.B.M., Singh, Naveena, Do, Viet, D'Amico, Romerai, Nout, Remi A., Feeney, Amanda, Verhoeven-Adema, Karen W., Putter, Hein, Creutzberg, Carien L., McCormack, Mary, Whitmarsh, Karen, Allerton, Rozenn, Gregory, Deborah, Symonds, Paul, Hoskin, Peter J., Adusumalli, Madhavi, Anand, Anjana, Wade, Robert, Stewart, Alexandra, Taylor, Wendy, Kruitwagen, Roy F.P.M., Hollema, Harry, Pras, Elizabeth, Snyers, An, Stalpers, Lukas, Jobsen, Jan J., Slot, Annerie, Mens, Jan Willem M., Stam, Tanja C., PORTEC study group, MS Radiotherapie, Cancer, de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B., Ledermann, Jonathan A., Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie Helene, Jürgenliemk-Schulz, Ina M., Kitchener, Henry C., Nijman, Hans W., Wilson, Godfrey, Brooks, Susan, Carinelli, Silvestro, Provencher, Diane, Hanzen, Chantal, Lutgens, Ludy C.H.W., Smit, Vincent T.H.B.M., Singh, Naveena, Do, Viet, D'Amico, Romerai, Nout, Remi A., Feeney, Amanda, Verhoeven-Adema, Karen W., Putter, Hein, Creutzberg, Carien L., McCormack, Mary, Whitmarsh, Karen, Allerton, Rozenn, Gregory, Deborah, Symonds, Paul, Hoskin, Peter J., Adusumalli, Madhavi, Anand, Anjana, Wade, Robert, Stewart, Alexandra, Taylor, Wendy, Kruitwagen, Roy F.P.M., Hollema, Harry, Pras, Elizabeth, Snyers, An, Stalpers, Lukas, Jobsen, Jan J., Slot, Annerie, Mens, Jan Willem M., Stam, Tanja C., and PORTEC study group

Published
2018

88. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1Promoter Hypermethylation

Author

Kaya, Merve, Post, Cathalijne C.B., Tops, Carli M., Nielsen, Maartje, Crosbie, Emma J., Leary, Alexandra, Mileshkin, Linda R., Han, Kathy, Bessette, Paul, de Boer, Stephanie M., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy, Jobsen, Jan J., Haverkort, Marie A.D., Nout, Remi A., Kroep, Judith, Creutzberg, Carien L., Smit, Vincent T.H.B.M., Horeweg, Nanda, van Wezel, Tom, and Bosse, Tjalling

Abstract

Universal tumor screening in endometrial carcinoma (EC) is increasingly adopted to identify individuals at risk of Lynch syndrome (LS). These cases involve mismatch repair-deficient (MMRd) EC without MLH1promoter hypermethylation (PHM). LS is confirmed through the identification of germline MMR pathogenic variants (PV). In cases where these are not detected, emerging evidence highlights the significance of double-somatic MMR gene alterations as a sporadic cause of MMRd, alongside POLE/POLD1exonuclease domain (EDM) PV leading to secondary MMR PV. Our understanding of the incidence of different MMRd EC origins not related to MLH1-PHM, their associations with clinicopathologic characteristics, and the prognostic implications remains limited.

Published
2024
Full Text
View/download PDF

89. Author Correction: Prediction of recurrence risk in endometrial cancer with multimodal deep learning

Author

Volinsky-Fremond, Sarah, Horeweg, Nanda, Andani, Sonali, Barkey Wolf, Jurriaan, Lafarge, Maxime W., de Kroon, Cor D., Ørtoft, Gitte, Høgdall, Estrid, Dijkstra, Jouke, Jobsen, Jan J., Lutgens, Ludy C. H. W., Powell, Melanie E., Mileshkin, Linda R., Mackay, Helen, Leary, Alexandra, Katsaros, Dionyssios, Nijman, Hans W., de Boer, Stephanie M., Nout, Remi A., de Bruyn, Marco, Church, David, Smit, Vincent T. H. B. M., Creutzberg, Carien L., Koelzer, Viktor H., and Bosse, Tjalling

Published
2024
Full Text
View/download PDF

90. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts

Author

Stelloo, Ellen, primary, Nout, Remi A., additional, Osse, Elisabeth M., additional, Jürgenliemk-Schulz, Ina J., additional, Jobsen, Jan J., additional, Lutgens, Ludy C., additional, van der Steen-Banasik, Elzbieta M., additional, Nijman, Hans W., additional, Putter, Hein, additional, Bosse, Tjalling, additional, Creutzberg, Carien L., additional, and Smit, Vincent T.H.B.M., additional

Published
2016
Full Text
View/download PDF

91. Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study

Author

Kirchheiner, Kathrin, primary, Pötter, Richard, additional, Tanderup, Kari, additional, Lindegaard, Jacob C., additional, Haie-Meder, Christine, additional, Petrič, Primož, additional, Mahantshetty, Umesh, additional, Jürgenliemk-Schulz, Ina M., additional, Rai, Bhavana, additional, Cooper, Rachel, additional, Dörr, Wolfgang, additional, Nout, Remi A., additional, Lindegaard, Jacob, additional, Fokdal, Lars, additional, Van Der Steen Banasik, Elzbieta, additional, Dumas, Isabelle, additional, Chargari, Cyrus, additional, Van Limbergen, Erik, additional, Segedin, Barbara, additional, Hudej, Robert, additional, Erickson, Beth, additional, Hoskin, Peter, additional, Lowe, Gerry, additional, Swamidas, Jamema, additional, Shrivastava, Shyam Kishore, additional, De Leeuw, Astrid, additional, Kirchheiner, Kathrin, additional, Lutgens, Ludy C.H.W., additional, Hadjiev, Janaki, additional, Bownes, Peter, additional, Sundset, Marit, additional, Bruheim, Kjersti, additional, Hellebust, Taran Paulsen, additional, Huang, Fleur, additional, Menon, Geetha, additional, Villafranca, Elena, additional, Oinam, Arun S., additional, Tan, Li Tee, additional, Bachand, Francois, additional, Jacobson, Geraldine, additional, Anttila, Maarit, additional, and Pieters, Bradley, additional

Published
2016
Full Text
View/download PDF

93. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer : A pooled analysis of PORTEC-1 and PORTEC-2 trials

Author

Creutzberg, Carien L., Van Stiphout, Ruud G.P.M., Nout, Remi A., Lutgens, Ludy C.H.W., Jürgenliemk-Schulz, Ina M., Jobsen, Jan J, Smit, Vincent T.H.B.M., Lambin, Philippe, Creutzberg, Carien L., Van Stiphout, Ruud G.P.M., Nout, Remi A., Lutgens, Ludy C.H.W., Jürgenliemk-Schulz, Ina M., Jobsen, Jan J, Smit, Vincent T.H.B.M., and Lambin, Philippe

Published
2015

94. Long-term impact of endometrial cancer diagnosis and treatment on health-related quality of life and cancer survivorship : Results from the randomized PORTEC-2 trial

Author

De Boer, Stephanie M., Nout, Remi A., Jurgenliemk-Schulz, Ina M., Jobsen, Jan J, Lutgens, Ludy C.H.W., Van Der Steen-Banasik, Elzbieta M., Mens, Jan Willem M., Slot, Annerie, Stenfert Kroese, Marika C., Oerlemans, Simone, Putter, Hein, Verhoeven-Adema, Karen W., Nijman, Hans W, Creutzberg, Carien L., De Boer, Stephanie M., Nout, Remi A., Jurgenliemk-Schulz, Ina M., Jobsen, Jan J, Lutgens, Ludy C.H.W., Van Der Steen-Banasik, Elzbieta M., Mens, Jan Willem M., Slot, Annerie, Stenfert Kroese, Marika C., Oerlemans, Simone, Putter, Hein, Verhoeven-Adema, Karen W., Nijman, Hans W, and Creutzberg, Carien L.

Published
2015

95. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer - A pooled analysis of PORTEC 1 and 2 trials

Author

MS Radiotherapie, Cancer, Bosse, Tjalling, Peters, Elke E.M., Creutzberg, Carien L., Jürgenliemk-Schulz, Ina M., Jobsen, Jan J, Mens, Jan Willem M., Lutgens, Ludy C.H.W., Van Der Steen-Banasik, Elzbieta M., Smit, Vincent T.H.B.M., Nout, Remi A., MS Radiotherapie, Cancer, Bosse, Tjalling, Peters, Elke E.M., Creutzberg, Carien L., Jürgenliemk-Schulz, Ina M., Jobsen, Jan J, Mens, Jan Willem M., Lutgens, Ludy C.H.W., Van Der Steen-Banasik, Elzbieta M., Smit, Vincent T.H.B.M., and Nout, Remi A.

Published
2015

96. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: A pooled analysis of PORTEC-1 and PORTEC-2 trials

Author

MS Radiotherapie, Cancer, Creutzberg, Carien L., Van Stiphout, Ruud G.P.M., Nout, Remi A., Lutgens, Ludy C.H.W., Jürgenliemk-Schulz, Ina M., Jobsen, Jan J, Smit, Vincent T.H.B.M., Lambin, Philippe, MS Radiotherapie, Cancer, Creutzberg, Carien L., Van Stiphout, Ruud G.P.M., Nout, Remi A., Lutgens, Ludy C.H.W., Jürgenliemk-Schulz, Ina M., Jobsen, Jan J, Smit, Vincent T.H.B.M., and Lambin, Philippe

Published
2015

97. Long-term impact of endometrial cancer diagnosis and treatment on health-related quality of life and cancer survivorship: Results from the randomized PORTEC-2 trial

Author

MS Radiotherapie, Cancer, De Boer, Stephanie M., Nout, Remi A., Jurgenliemk-Schulz, Ina M., Jobsen, Jan J, Lutgens, Ludy C.H.W., Van Der Steen-Banasik, Elzbieta M., Mens, Jan Willem M., Slot, Annerie, Stenfert Kroese, Marika C., Oerlemans, Simone, Putter, Hein, Verhoeven-Adema, Karen W., Nijman, Hans W, Creutzberg, Carien L., MS Radiotherapie, Cancer, De Boer, Stephanie M., Nout, Remi A., Jurgenliemk-Schulz, Ina M., Jobsen, Jan J, Lutgens, Ludy C.H.W., Van Der Steen-Banasik, Elzbieta M., Mens, Jan Willem M., Slot, Annerie, Stenfert Kroese, Marika C., Oerlemans, Simone, Putter, Hein, Verhoeven-Adema, Karen W., Nijman, Hans W, and Creutzberg, Carien L.

Published
2015

98. Critical assessment of intramodality 3D ultrasound imaging for prostate IGRT compared to fiducial markers

Author

van der Meer, Skadi, Bloemen-van Gurp, Esther, Hermans, Jolanda, Voncken, Robert, Heuvelmans, Denys, Gubbels, Carol, Fontanarosa, Davide, Visser, Peter, Lutgens, Ludy, van Gils, Francis, Verhaegen, Frank, Promovendi ODB, Radiotherapie, Kindergeneeskunde, Genetica & Celbiologie, Psychiatrie & Neuropsychologie, and RS: GROW - School for Oncology and Reproduction

Subjects
minimal pressure, fiducial markers, interoperator and intraoperator variability, image guided radiation therapy, electronic portal imaging, speed of sound correction, prostate localization, intramodality 3D ultrasound
Abstract

Purpose: A quantitative 3D intramodality ultrasound (US) imaging system was verified for daily in-room prostate localization, and compared to prostate localization based on implanted fiducial markers (FMs). Methods: Thirteen prostate patients underwent multiple US scans during treatment. A total of 376 US-scans and 817 matches were used to determine the intra-and interoperator variability. Additionally, eight other patients underwent daily prostate localization using both US and electronic portal imaging (EPI) with FMs resulting in 244 combined US-EPI scans. Scanning was performed with minimal probe pressure and a correction for the speed of sound aberration was performed. Uncertainties of both US and FM methods were assessed. User variability of the US method was assessed. Results: The overall US user variability is 2.6 mm. The mean differences between US and FM are: 2.5 +/- 4.0 mm (LR), 0.6 +/- 4.9 mm (SI), and -2.3 +/- 3.6 mm (AP). The intramodality character of this US system mitigates potential errors due to transducer pressure and speed of sound aberrations. Conclusions: The overall accuracy of US (3.0 mm) is comparable to our FM workflow (2.2 mm). Since neither US nor FM can be considered a gold standard no conclusions can be drawn on the superiority of either method. Because US imaging captures the prostate itself instead of surrogates no invasive procedure is required. It requires more effort to standardize US imaging than FM detection. Since US imaging does not involve a radiation burden, US prostate imaging offers an alternative for FM EPI positioning.

Published
2013

99. Dose reduction in LDR brachytherapy by implanted prostate gold fiducial markers

Author

Landry, Guillaume, Reniers, Brigitte, Lutgens, Ludy, Murrer, Lars, Afsharpour, Hossein, de Haas-Kock, Danielle, Visser, Peter, van Gils, Francis, Verhaegen, Frank, Radiotherapie, and RS: GROW - School for Oncology and Reproduction

Subjects
fiducial markers, brachytherapy, prostate cancer, Monte Carlo, cold spot
Abstract

Purpose: The dosimetric impact of gold fiducial markers ( FM) implanted prior to external beam radiotherapy of prostate cancer on low dose rate (LDR) brachytherapy seed implants performed in the context of combined therapy was investigated. Methods: A virtual water phantom was designed containing a single FM. Single and multi source scenarios were investigated by performing Monte Carlo dose calculations, along with the influence of varying orientation and distance of the FM with respect to the sources. Three prostate cancer patients treated with LDR brachytherapy for a recurrence following external beam radiotherapy with implanted FM were studied as surrogate cases to combined therapy. FM and brachytherapy seeds were identified on post implant CT scans and Monte Carlo dose calculations were performed with and without FM. The dosimetric impact of the FM was evaluated by quantifying the amplitude of dose shadows and the volume of cold spots. D-90 was reported based on the post implant CT prostate contour. Results: Large shadows are observed in the single source-FM scenarios. As expected from geometric considerations, the shadows are dependent on source-FM distance and orientation. Large dose reductions are observed at the distal side of FM, while at the proximal side a dose enhancement is observed. In multisource scenarios, the importance of shadows appears mitigated, although FM at the periphery of the seed distribution caused underdosage (

Published
2012

100. Sensitivity of low energy brachytherapy Monte Carlo dose calculations to uncertainties in human tissue composition

Author

Landry, Guillaume, Reniers, Brigitte, Murrer, Lars, Lutgens, Ludy, Bloemen-van Gurp, Esther J., Pignol, Jean-Philippe, Keller, Brian, Beaulieu, Luc, Verhaegen, Frank, Radiotherapie, and RS: GROW - School for Oncology and Reproduction

Subjects
tissue composition, brachytherapy, seed implants, dose calculation, Monte Carlo
Abstract

Purpose: The objective of this work is to assess the sensitivity of Monte Carlo (MC) dose calculations to uncertainties in human tissue composition for a range of low photon energy brachytherapy sources: I-125, Pd-103, (CS)-C-131, and an electronic brachytherapy source (EBS). The low energy photons emitted by these sources make the dosimetry sensitive to variations in tissue atomic number due to the dominance of the photoelectric effect. This work reports dose to a small mass of water in medium D-w,D-m as opposed to dose to a small mass of medium in medium D-m,D-m. Methods: Mean adipose, mammary gland, and breast tissues (as uniform mixture of the aforementioned tissues) are investigated as well as compositions corresponding to one standard deviation from the mean. Prostate mean compositions from three different literature sources are also investigated. Three sets of MC simulations are performed with the GEANT4 code: (1) Dose calculations for idealized TG-43-like spherical geometries using point sources. Radial dose profiles obtained in different media are compared to assess the influence of compositional uncertainties. (2) Dose calculations for four clinical prostate LDR brachytherapy permanent seed implants using I-125 seeds (Model 2301, Best Medical, Springfield, VA). The effect of varying the prostate composition in the planning target volume (PTV) is investigated by comparing PTV D-90 values. (3) Dose calculations for four clinical breast LDR brachytherapy permanent seed implants using Pd-103 seeds (Model 2335, Best Medical). The effects of varying the adipose/gland ratio in the PTV and of varying the elemental composition of adipose and gland within one standard deviation of the assumed mean composition are investigated by comparing PTV D-90 values. For (2) and (3), the influence of using the mass density from CT scans instead of unit mass density is also assessed. Results: Results from simulation (1) show that variations in the mean compositions of tissues affect low energy brachytherapy dosimetry. Dose differences between mean and one standard deviation of the mean composition increasing with distance from the source are observed. It is established that the I-125 and Cs-131 sources are the least sensitive to variations in elemental compositions while Pd-103 is most sensitive. The EBS falls in between and exhibits complex behavior due to significant spectral hardening. Results from simulation (2) show that two prostate compositions are dosimetrically equivalent to water while the third shows D-90 differences of up to 4%. Results from simulation (3) show that breast is more sensitive than prostate with dose variations of up to 30% from water for 70% adipose/30% gland breast. The variability of the breast composition adds a +/- 10% dose variation. Conclusions: Low energy brachytherapy dose distributions in tissue differ from water and are influenced by density, mean tissue composition, and patient-to-patient composition variations. The results support the use of a dose calculation algorithm accounting for heterogeneities such as MC. Since this work shows that variations in mean tissue compositions affect MC dosimetry and result in increased dose uncertainties, the authors conclude that imaging tools providing more accurate estimates of elemental compositions such as dual energy CT would be beneficial.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results